EFPIA

Views & Analysis

New IFPMA and EFPIA guidance on use of social media by the p...

On 28 September 2022, the international and European self-regulatory bodies for the research-based pharmaceutical industry (I

Market Access

Are timely access and robust safety mutually exclusive?

The FDA approves new cancer treatments in half the time of the EMA – but does faster mean better? And how can regulators balance timely access with robust safety?

Digital

Top 5 takeaways from international hybrid and virtual meetin...

The move to online international meetings has left pharma companies with uncertainty around contact compliance.

News

Drugmakers pledge shorter launch times for drugs in EU

Pharmaceutical companies have said they will try to carve months off the time between approval and launch for new medicines in Europe, and reduce disparities in access between countries.

Views & Analysis